港股异动 | 巨子生物(02367)盘中涨超8% 全球首个注射用重组胶原蛋白和透明质酸钠复合溶液获批

智通财经02-05

智通财经APP获悉，巨子生物(02367)盘中涨超8%，截至发稿，涨7.03%，报34.4港元，成交额2.56亿港元。消息面上，巨子生物近日宣布，旗下“重组I型α1亚型胶原蛋白及透明质酸钠复合溶液”三类医疗器械获批。该产品是全球首个用于改善面颊部平滑度的重组胶原蛋白和透明质酸钠复合溶液植入剂产品，通过器审与药审联合审评正式获批。中金表示，看好该产品的获批进一步拓展医美产品矩阵，印证公司领先技术研发...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2609346392?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-05 10:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609346392","market":"hk","top_or_hot":-1,"title":"港股异动 | 巨子生物(02367)盘中涨超8% 全球首个注射用重组胶原蛋白和透明质酸钠复合溶液获批","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，巨子生物(02367)盘中涨超8%，截至发稿，涨7.03%，报34.4港元，成交额2.56亿港元。消息面上，巨子生物近日宣布，旗下“重组I型α1亚型胶原蛋白及透明质酸钠复合溶液”三类医疗器械获批。该产品是全球首个用于改善面颊部平滑度的重组胶原蛋白和透明质酸钠复合溶液植入剂产品，通过器审与药审联合审评正式获批。中金表示，看好该产品的获批进一步拓展医美产品矩阵，印证公司领先技术研发...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401910.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 巨子生物(02367)盘中涨超8% 全球首个注射用重组胶原蛋白和透明质酸钠复合溶液获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 巨子生物(02367)盘中涨超8% 全球首个注射用重组胶原蛋白和透明质酸钠复合溶液获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-05 10:37 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1401910.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，巨子生物(02367)盘中涨超8%，截至发稿，涨7.03%，报34.4港元，成交额2.56亿港元。消息面上，巨子生物近日宣布，旗下“重组I型α1亚型胶原蛋白及透明质酸钠复合溶液”三类医疗器械获批。该产品是全球首个用于改善面颊部平滑度的重组胶原蛋白和透明质酸钠复合溶液植入剂产品，通过器审与药审联合审评正式获批。中金表示，看好该产品的获批进一步拓展医美产品矩阵，印证公司领先技术研发...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401910.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1401910.html","article_id":"2609346392","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609346392","pubTimestamp":1770259040,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，巨子生物(02367)盘中涨超8%，截至发稿，涨7.03%，报34.4港元，成交额2.56亿港元。消息面上，巨子生物近日宣布，旗下“重组I型α1亚型胶原蛋白及透明质酸钠复合溶液”三类医疗器械获批。该产品是全球首个用于改善面颊部平滑度的重组胶原蛋白和透明质酸钠复合溶液植入剂产品，通过器审与药审联合审评正式获批。中金表示，看好该产品的获批进一步拓展医美产品矩阵，印证公司领先技术研发实力。展望中长期，该行认为公司研发实力、品牌心智、团队凝聚力仍稳固，后续随着化妆品基本盘修复向好、医美贡献增量，建议关注布局机会。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK4585":"ETF&股票定投概念","02367":"巨子生物","02357":"中航科工","BK1589":"北水核心资产","BK1211":"航天航空与国防","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","VT":"世界全股市ETF-Vanguard","BK1207":"个人用品","SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD"},"translate_title":"Changes in Hong Kong stocks | Juzi Biotech (02367) rose more than 8% intraday, the world's first recombinant collagen and sodium hyaluronate composite solution for injection was approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VT":1.5,"VXUS":1.5,"02357":0.9,"02367":1.5},"content_text":"智通财经APP获悉，巨子生物(02367)盘中涨超8%，截至发稿，涨7.03%，报34.4港元，成交额2.56亿港元。消息面上，巨子生物近日宣布，旗下“重组I型α1亚型胶原蛋白及透明质酸钠复合溶液”三类医疗器械获批。该产品是全球首个用于改善面颊部平滑度的重组胶原蛋白和透明质酸钠复合溶液植入剂产品，通过器审与药审联合审评正式获批。中金表示，看好该产品的获批进一步拓展医美产品矩阵，印证公司领先技术研发实力。展望中长期，该行认为公司研发实力、品牌心智、团队凝聚力仍稳固，后续随着化妆品基本盘修复向好、医美贡献增量，建议关注布局机会。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609346392","isCrawlerRequest":true}